Detalles de la búsqueda
1.
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
JCI Insight
; 7(3)2022 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35132961
2.
Differential EphA2 epitope display on normal versus malignant cells.
Cancer Res
; 63(22): 7907-12, 2003 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14633720
3.
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mol Cancer Ther
; 2(2): 183-8, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12589035
4.
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Mol Cancer Ther
; 8(8): 2131-41, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19671750
5.
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Neoplasia
; 11(6): 509-17, 2 p following 517, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19484140
6.
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
J Natl Cancer Inst
; 98(21): 1558-70, 2006 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17077358
Resultados
1 -
6
de 6
1
Próxima >
>>